This report evaluates whether full-text clinical studies and clinical practice guidelines and position statements support the use of gene replacement therapy with onasemnogene abeparvovec-xioi (OA) for spinal muscular atrophy due to mutations in the survival motor neuron (SMN) 1 gene. OA is intended as a once-per-lifetime therapy.